<DOC>
	<DOC>NCT02061670</DOC>
	<brief_summary>The purpose of this study is to determine whether it is safe to administer Ragweed-SPIRE to subjects suffering from both ragweed allergy and asthma.</brief_summary>
	<brief_title>Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
	<criteria>Male or female, aged 1865 years. Asthma treated by inhaled SABA or inhaled SABA plus lowmedium dose ICS in 6 weeks prior to randomisation. A reliable history consistent with moderate to severe rhinoconjunctivitis on exposure to ragweed for at least the previous two ragweed seasons. Positive skin prick test to ragweed Ragweedspecific Immunoglobulin E (IgE) â‰¥ 0.35 kU/L. History of lifethreatening asthma. Uncontrolled asthma according to GINA FEV1 of &lt; 70 % of predicted, regardless of the cause. Administration of adrenaline (epinephrine) is contraindicated (e.g. subjects with acute or chronic symptomatic coronary heart disease or severe hypertension). History of severe drug allergy or anaphylactic reaction to food. A history of any significant disease or disorder (e.g. immune system, pulmonary, cardiovascular, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment, history of alcohol or drug abuse)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Ragweed</keyword>
	<keyword>Allergy</keyword>
	<keyword>rhinoconjunctivitis</keyword>
	<keyword>rhinitis</keyword>
	<keyword>asthma</keyword>
</DOC>